Adial Pharmaceuticals (ADIL) Non-Current Deferred Tax Liability (2020 - 2023)
Adial Pharmaceuticals (ADIL) posted Non-Current Deferred Tax Liability of $437.0 for Q4 2023, down 98.09% sequentially from $22897.0 in Q1 2023, and up 13.8% YoY from $384.0 in Q4 2022.
Adial Pharmaceuticals (ADIL) Non-Current Deferred Tax Liability (2020 - 2023) Analysis & Trends
Adial Pharmaceuticals has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $437.0 in Q4 2023.
- Quarterly Non-Current Deferred Tax Liability rose 13.8% year-over-year to $437.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $437.0 (up 13.8% YoY) and the FY2023 annual result came in at $437.0, up 13.8% from the prior year.
- Non-Current Deferred Tax Liability fell to $437.0 in Q4 2023 per ADIL's latest filing, from $22897.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $23399.0 in Q4 2021 and troughed at $296.0 in Q4 2020.
- A 4-year average of $14701.2 and a median of $23148.0 in 2021 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability surged 7805.07% in 2021, then tumbled 98.36% in 2022.
- Over 4 years, Non-Current Deferred Tax Liability stood at $296.0 in 2020, then soared by 7805.07% to $23399.0 in 2021, then sank by 98.36% to $384.0 in 2022, then advanced by 13.8% to $437.0 in 2023.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $437.0, $22897.0, and $384.0 for Q4 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 437.00 |
| Dec 31, 2023 | 437.00 |
| Mar 31, 2023 | 22,897.00 |
| Mar 31, 2023 | 22,897.00 |
| Dec 31, 2022 | 384.00 |
| Dec 31, 2022 | 384.00 |
| Sep 30, 2022 | 23,399.00 |
| Sep 30, 2022 | 23,399.00 |
| Jun 30, 2022 | 23,399.00 |
| Jun 30, 2022 | 23,399.00 |
| Mar 31, 2022 | 23,399.00 |
| Mar 31, 2022 | 23,399.00 |
| Dec 31, 2021 | 23,399.00 |
| Dec 31, 2021 | 23,399.00 |
| Dec 31, 2020 | 296.00 |
| Dec 31, 2020 | 296.00 |